 |
인쇄하기
취소
|
Diovan takes on Norvasc
Novartis Korea is enjoying brisk sales of its antihypertensive agent, Diovan (valsartan).
Sales of Novartis Korea's antihypertensive medicine are estimated at 78 billion won last year, making it one of the top-selling drugs in the country.
Diovan, an angiotensin II receptor blocker (ARB), is the top-prescribed ARB franchise in the U.S. after its approval from the US FDA on August 2002 and...
Sales of Novartis Korea's antihypertensive medicine are estimated at 78 billion won last year, making it one of the top-selling drugs in the country.
Diovan, an angiotensin II receptor blocker (ARB), is the top-prescribed ARB franchise in the U.S. after its approval from the US FDA on August 2002 and...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.